Figure 5.

Summary of this study. In this multicenter prospective open-labeled study, the effects of candesartan (CAN; n=67) or amlodipine (AML; n=64) on presurgical abdominal aortic aneurysm (AAA) growth and associated biomarkers in the Japanese population were evaluated. AML may prevent AAA growth in patients with chronic kidney disease (CKD) or lower systolic blood pressure (SBP; <130 mmHg), associated with a decline in plasma renin activity (PRA) and circulating high-sensitivity C-reactive protein (hs-CRP). Parts of the figure were drawn using pictures from Servier Medical Art. ARB, angiotensin receptor blocker; BP, blood pressure; CCB, calcium channel blocker; CT, computed tomography; LDL, low-density lipoprotein; MDA, malondialdehyde; MMPs, matrix metalloproteinases; PRA, plasma renin activity; psAAA, abdominal aortic aneurysm at the presurgical stage; RAS, renin-angiotensin system; TGF-β, transforming growth factor-β; Tx, treatment.